Press Releases : BioMarin http://investors.biomarin.com/ BioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco http://investors.biomarin.com/2018-01-03-BioMarin-to-Present-at-36th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco Wed, 03 Jan 2018 05:30:00 -0800 http://investors.biomarin.com/2018-01-03-BioMarin-to-Present-at-36th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 http://investors.biomarin.com/2017-12-22-BioMarin-Receives-Anticipated-Notification-of-PDUFA-Extension-for-Pegvaliase-Biologics-License-Application-BLA-to-May-28-2018 Regulatory Review Process Proceeding In-line with Company's Expectations Fri, 22 Dec 2017 05:30:00 -0800 http://investors.biomarin.com/2017-12-22-BioMarin-Receives-Anticipated-Notification-of-PDUFA-Extension-for-Pegvaliase-Biologics-License-Application-BLA-to-May-28-2018 BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A http://investors.biomarin.com/2017-12-19-BioMarin-Doses-First-Patient-in-Global-GENEr8-1-Phase-3-Study-of-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A Second Phase 3 Study, GENEr8-2, to Begin at the Start of 2018 Tue, 19 Dec 2017 13:05:00 -0800 http://investors.biomarin.com/2017-12-19-BioMarin-Doses-First-Patient-in-Global-GENEr8-1-Phase-3-Study-of-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting http://investors.biomarin.com/2017-12-11-BioMarin-Highlights-New-Results-for-Gene-Therapy-Valoctocogene-Roxaparvovec-at-the-2017-American-Society-of-Hemophilia-ASH-Meeting New 1.5 Year Results Demonstrating 6e13 vg/kg Dose Achieved Sustained Factor VIII Levels within the Normal Range in Severe Hemophilia A for Most Patients Mon, 11 Dec 2017 07:00:00 -0800 http://investors.biomarin.com/2017-12-11-BioMarin-Highlights-New-Results-for-Gene-Therapy-Valoctocogene-Roxaparvovec-at-the-2017-American-Society-of-Hemophilia-ASH-Meeting BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication http://investors.biomarin.com/2017-12-09-BioMarin-Provides-1-5-years-of-Clinical-Data-for-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A-at-59th-American-Society-of-Hematology-ASH-Annual-Meeting-Concurrent-with-NEJM-Publication Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study Sat, 09 Dec 2017 04:30:00 -0800 http://investors.biomarin.com/2017-12-09-BioMarin-Provides-1-5-years-of-Clinical-Data-for-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A-at-59th-American-Society-of-Hematology-ASH-Annual-Meeting-Concurrent-with-NEJM-Publication